Status:
NOT_YET_RECRUITING
Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence
Lead Sponsor:
Zhejiang Provincial People's Hospital
Collaborating Sponsors:
The Second Affiliated Hospital of Harbin Medical University
Conditions:
Glioblastoma Multiforme (GBM)
Eligibility:
All Genders
18+ years
Brief Summary
GBM patients receiving PDT treatment (50 cases，surgery combined with photodynamic therapy) and traditional treatment (50 cases，traditional surgery) in our hospital and partner hospitals were collected...
Eligibility Criteria
Inclusion
- Pathologically confirmed primary focal GBM; Recurrent GBM(single or satellite lesions); Multiple (multiple germinal centers)GBM.
Exclusion
- Photosensitizer allergy.
- Severe coagulation disorder.
- Patients with severe cardiovascular and cerebrovascular diseases, especially patients in the acute stage.
- Multiple organ failure, end-stage patients. ⑤ Pregnant women: Photofrin is considered a class C pregnancy risk (toxic, non-teratogenic) drug with non-dialysis properties.
- Non-gbm diagnosis: Patients with other types of brain tumors or diseases. 7 Do not agree to informed consent: patients who are unwilling to sign informed consent or do not agree to participate in the study.
Key Trial Info
Start Date :
June 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06939400
Start Date
June 1 2025
End Date
December 31 2027
Last Update
April 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China, 310014